---
title: "AOD-9604"
canonical_url: https://peptidelibrary.app/library/aod-9604
description: "Modified C-terminal hGH fragment studied for lipolysis without GH-receptor growth effects. Not FDA-approved. WADA prohibits GH fragments including AOD-9604 (S2)."
updated: 2026-09-26
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# AOD-9604

AOD-9604 (also called hGH fragment 176–191 analog or Tyr-hGH 177–191) is a GH C-terminal fragment analog. AOD-9604 is a synthetic analog of the C-terminal fragment of human growth hormone, residues 176 to 191, with an added tyrosine.

Modified C-terminal hGH fragment studied for lipolysis without GH-receptor growth effects. Not FDA-approved. WADA prohibits GH fragments including AOD-9604 (S2).

Also known as: hGH fragment 176–191 analog, Tyr-hGH 177–191.

Categories: Fat Loss, Muscle/Recovery, GLP-1/Metabolic, Experimental.

## Classification

- Type: GH C-terminal fragment analog
- Mechanism class: Lipolytic GH fragment
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

AOD-9604 is a synthetic analog of the C-terminal fragment of human growth hormone, residues 176 to 191, with an added tyrosine. That region was identified as the part of the growth hormone molecule associated with fat metabolism, and the design intent was to separate lipolytic activity from the growth-promoting and glucose-altering effects of the intact hormone, which are mediated through the growth hormone receptor. In rodent models the fragment increased lipolysis and reduced lipogenesis without raising IGF-1 or impairing insulin sensitivity. Human obesity trials did not reproduce a meaningful weight effect, and development for that indication was not pursued to approval.

Targets: Adipose lipolytic pathways.

Origin: Synthetic analog of hGH residues 176–191 with an N-terminal tyrosine.

## Properties

- Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
- Length: 16
- Molecular formula: C78H123N23O23S2
- Molecular weight: 1,815.1 g/mol
- CAS number: 221231-10-3
- Half-life: ~20-30 minutes

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 1
- Latest source: 2026

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004. 2004. Secondary report (review or programme summary), not a trial. Population: Development-stage summary, not a reported trial result. Obesity programme status. Limitations: Reported in research, not a controlled trial. [Source](https://pubmed.ncbi.nlm.nih.gov/15134286/)
2. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injury. Sports Med. 2026. 2026. Secondary report (review or programme summary), not a trial. Population: Review of approved and unapproved peptides. Safety and efficacy assessment. Limitations: Reported in research, not a controlled trial. [Source](https://pubmed.ncbi.nlm.nih.gov/41966639/)
3. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015. 2015. Preclinical: animal or lab study. Population: In vitro metabolism. Detection and metabolism of AOD9604. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/25208511/)

## Safety

Side effects: Injection-site reactions; Headache; Limited efficacy in human trials.

Risks: WADA S2 prohibited; Not approved for weight loss.

Contraindications: Cancer history.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

AOD-9604 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is AOD-9604?

Modified C-terminal hGH fragment studied for lipolysis without GH-receptor growth effects. Not FDA-approved. WADA prohibits GH fragments including AOD-9604 (S2). AOD-9604 is a synthetic analog of the C-terminal fragment of human growth hormone, residues 176 to 191, with an added tyrosine. That region was identified as the part of the growth hormone molecule associated with fat metabolism, and the design intent was to separate lipolytic activity from the growth-promoting and glucose-altering effects of the intact hormone, which are mediated through the growth hormone receptor.

### What are the side effects of AOD-9604?

AOD-9604 has no controlled human safety data, so its side-effect profile is not well established. Effects recorded on this profile include injection-site reactions and headache. Cautions recorded on this profile: cancer history. It is on the WADA Prohibited List for athletes. This is reference information, not medical advice.

### How does AOD-9604 work?

AOD-9604 is a synthetic analog of the C-terminal fragment of human growth hormone, residues 176 to 191, with an added tyrosine. That region was identified as the part of the growth hormone molecule associated with fat metabolism, and the design intent was to separate lipolytic activity from the growth-promoting and glucose-altering effects of the intact hormone, which are mediated through the growth hormone receptor.

### Is AOD-9604 FDA approved?

No. AOD-9604 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A nomination: Previously in Category 2; nomination withdrawn by the nominators.

### What is the half-life of AOD-9604?

Reported half-life for AOD-9604 is ~20-30 minutes. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of AOD-9604?

AOD-9604 has the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, giving a chain of 16 amino acids. Its molecular formula is C78H123N23O23S2.

### Is AOD-9604 banned in sport?

AOD-9604 is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [AOD-9604 Metabolic — Curr Opin Investig Drugs, 2004](https://pubmed.ncbi.nlm.nih.gov/15134286/)
- [Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026](https://pubmed.ncbi.nlm.nih.gov/41490200/)
- [Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports Med, 2026](https://pubmed.ncbi.nlm.nih.gov/41966639/)
- [AOD-9604 does not influence the WADA hGH isoform immunoassay — Drug Test Anal, 2013](https://pubmed.ncbi.nlm.nih.gov/24124033/)
- [Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls — J Pharm Biomed Anal, 2014](https://pubmed.ncbi.nlm.nih.gov/24906629/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
